At ViGeneron, we’re experts in developing new gene therapy solutions.
While we’re focused on gene therapy to cure ophthalmic diseases, our next-generation gene therapy technology platforms also offer opportunities for use in other diseases such as those affecting the central nervous system, liver, or cardiovascular system.
The vgAAV vector platform, based on novel engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes enable intravitreal, less invasive gene delivery but also allows vgAAV vectors to target a broad spectrum of cell types in the retina and potentially in other tissues, such as the central nervous system.
In addition, our REVeRT vector platform utilizes a unique mRNA trans-splicing technology to develop safe and effective AAV gene therapy targeting large genes (>5Kb). REVeRT achieves high reconstitution efficiencies at the mRNA and protein level and is broadly applicable for various disease areas.
We are actively looking to work with leading biopharmaceutical companies or academics that wish to exploit these opportunities.
If you are interested in our technologies, please contact us: firstname.lastname@example.org
LMU is recognized as one of Europe's premier academic and research institutions. The research group of Professor Martin Biel at the Department of Pharmacy attracts scholars and talented students from all over the world. Outstanding scientists work there to develop new techniques for advanced gene therapies.
WuXi Advanced Therapies
The Advanced Therapies business unit of WuXi AppTec is dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.